Overview

TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined with ifosfamide and then the efficacy of this combination in terms of overall response rate, time to progression and time of response
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Istituto Clinico Humanitas
Treatments:
Doxorubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin